AAHI Taps Quratis as Preferred Vaccine Manufacturer

Access to Advanced Health Institute (AAHI) has selected Quratis, a biotechnology company and advanced CDMO, as its preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies. This collaboration aims to accelerate the development of AAHI’s vaccine candidates targeting deadly diseases such as tuberculosis, and of vaccines that rely on AAHI’s vaccine adjuvants to provide protection against malaria, HIV, and other global health threats.

Quratis brings a GMP-certified bioplant and CDMO expertise in biopharmaceutical raw material development, process optimization, and finished pharmaceutical manufacturing. By designating Quratis as a preferred partner, AAHI strengthens both its scientific capabilities and access to scalable, cost-effective production of its vaccine formulations—including dry vaccines that eliminate cold chain dependencies and needle-free delivery systems for superior respiratory protection.

The partnership ensures a seamless supply chain platform, enabling swift clinical development and broader deployment to the world’s most vulnerable populations.

“Partnering with Quratis is a very important step in AAHI’s strategy to advance practical, life-saving vaccines, that can be deployed at scale where they’re needed most,” said Keeley Foley, CEO of AAHI. “Quartis’ innovative, cutting-edge, safe, world-class CDMO capabilities make it possible for AAHI to deliver on our mission – and help ensure our efforts to combat infectious diseases and foster health autonomy worldwide.”

“We are honored and thrilled to join forces with AAHI, a pioneer in immune-enhancing technologies and sustainable vaccine solutions,” said Soung Joon Kim, CEO of Quratis. “This partnership aligns perfectly with our vision of making people happy and healthy through borderless healthcare innovations. By supporting AAHI’s pipeline, we expect to create value not only for global health, but also for our shareholders through long-term growth opportunities.”

The partnership builds on existing collaborations, including the co-development of the ID93+GLA-SE tuberculosis vaccine candidate (QTP101).